Objective: To investigate the effects of different hemodialysis treatments on abnormal mineral and bone metabolism in patients with chronic renal failure. Methods: A random number table was used to divide 80 patients with chronic renal failure admitted to our hospital from January 2018 to January 2019 into 2 groups, with 40 cases in each group. Group A was treated with low-flux hemodialysis, and group B was treated with high-flux hemodialysis. The related indicators of mineral and bone metabolism of the two groups were compared. Results: Before treatment, the blood calcium, blood phosphorus, intact parathyroid hormone (iPTH), type I procollagen amino terminal peptide (PINP), fibroblast growth factor 23 (FGF23), serum creatinine (Scr) indicators of the two groups were compared. The difference was not statistically significant(P>0.05); After treatment, the blood calcium levels of the two groups were higher than before treatment, the blood phosphorus, iPTH, PINP, FGF23, and Scr levels were lower than before treatment, and the blood calcium level of group B was higher than that of group A, while blood phosphorus, iPTH, PINP, FGF23, and Scr levels were lower than group A, the difference was statistically significant (P<0.05). Conclusion: Compared with low-flux hemodialysis, patients with chronic renal failure treated with high-flux hemodialysis have better results, which can correct abnormal bone metabolism and improve Scr levels.